Best Mackinac County Grants for Nonprofits in Michigan

The OREF/John W. Brown Early-Stage Investigator Grant supports innovative research in musculoskeletal health, encouraging early-stage investigators to submit proposals utilizing enabling technologies. Established by the Orthopaedic Research and Education Foundation, this grant honors John W. Brown's contributions to orthopaedics. With a maximum funding of $100,000 over one or two years, the grant aims to enhance clinical practice and improve patient outcomes through groundbreaking research.

The SAA Shakespeare Publics Award, presented by the Shakespeare Association of America, celebrates innovative efforts that engage diverse publics with Shakespeare's works. Open to SAA members, the award recognizes projects that promote teaching, scholarship, performance, and activism. Since its inception in 1972, the SAA has fostered dialogue and collaboration among scholars, enhancing the appreciation of Shakespeare's impact on culture. This award highlights the importance of broadening access to Shakespeare's legacy in today's society.

The SAA First Book Award, presented by the Shakespeare Association of America (SAA), honors the legacy of Jerome Singerman and supports early career scholars. This prestigious award recognizes the best monograph with a significant Shakespeare component, published as the first book by a current SAA member between September 1, 2024, and September 1, 2025. The award will be announced during the SAA’s Annual Luncheon, celebrating contributions to Shakespeare studies.

The J. Leeds Barroll Dissertation Prize, awarded by the Shakespeare Association of America, honors exemplary doctoral work with a significant focus on Shakespeare. This prestigious award is conferred annually during the SAA’s Annual Luncheon. To be eligible, applicants must be SAA members in good standing, and dissertations must be approved between September 1, 2024, and September 1, 2025. This prize encourages innovative research and scholarship in Shakespeare studies.

The Barbara Hodgdon Award, presented by the Shakespeare Association of America (SAA), honors exceptional scholarship in the field of Shakespeare and Performance. Established in memory of Barbara Hodgdon, this award encourages innovative research across various media and time periods related to Shakespeare's work. Eligible submissions must be authored by SAA members and published two years prior to the award presentation. This recognition promotes new discussions and insights within the realm of Shakespearean performance studies.

The Faculty Travel Grant for AGU Annual Meeting supports early-to-mid career faculty from under-resourced institutions, including community colleges and minority-serving institutions. This program aims to facilitate attendance at the AGU Annual Meeting, which attracts over 22,000 geoscience professionals globally. Awardees receive a $1,700 travel stipend, access to professional development workshops, and networking opportunities, enabling them to enhance their research and teaching capabilities through collaboration and innovation.

Project Lead The Way is offering a rolling grant for schools to implement the PLTW Biomedical Science program for the 2026-2029 academic years. Eligible schools can receive up to $14,000 to cover participation fees and training costs. This grant encourages public, private, and charter schools across the U.S. to enhance their science curriculum, supporting students with engaging, hands-on learning experiences. Schools must commit to offering specific courses during the grant period to qualify for funding.

The Morris Animal Foundation invites proposals for the Feline Health Fellowship Training Award, aimed at advancing the health and welfare of domesticated cats. This program supports new investigators by providing salary funds in a mentoring environment. Proposals should focus on hypothesis-driven research with high scientific merit, targeting community and pet cats (Felis catus). The maximum award duration is 24 months, with budgets not exceeding $145,000. Join us in making impactful contributions to feline health.

The Morris Animal Foundation offers the Annual Feline Proposals: Feline Health Established Investigator Award to support research aimed at improving the health and welfare of domesticated cats. Established in 1948, the foundation funds innovative, hypothesis-driven studies that demonstrate high scientific merit. This grant encourages collaboration between academia and industry and has a maximum project duration of 36 months, with average awards around $100,000. Eligible proposals should focus solely on domesticated cats, excluding other feline species.

The Morris Animal Foundation offers the Annual Feline Health Pilot Study Award to support innovative research that enhances the health and welfare of domesticated cats. This funding is aimed at proof-of-concept studies, advancing animal health research through collaborative projects. With a maximum funding of $20,000 for a 12-month duration, the foundation seeks proposals that have a significant impact on both scientific and community stakeholders, ensuring a healthier future for feline populations.

The Morris Animal Foundation is dedicated to improving the health of animals through scientific research and funding. With a focus on domesticated cats, the Feline Health First Award supports innovative research that addresses the welfare of both community and pet cats. Grants are available for projects lasting up to 24 months, with a maximum budget of $120,000. This initiative encourages collaborations that translate research findings into practical applications for veterinarians and cat caretakers.

The Alzheimer’s Association Research Grant For All (AARGA) Program supports early-career investigators in their first seven years as independent researchers. This grant aims to fund projects that develop preliminary data and test new hypotheses in Alzheimer’s and related dementia research. Areas of interest include disease mechanisms, biomarker development, and health equity. Applications are welcome from both U.S. and international researchers, fostering innovation and collaboration in the fight against dementia.

The Waldenstrom Macroglobulinemia Fund provides crucial financial assistance to underinsured patients suffering from this rare blood cancer. Through the HealthWell Foundation, the fund helps cover prescription copays, insurance premiums, and treatment-related costs, ensuring access to necessary medical care. With over $1.2 billion in grants awarded, the program has supported more than 1.1 million patients since its inception in 2004. Its mission is to alleviate financial barriers to essential healthcare, allowing patients to focus on their treatment and recovery.

The Systemic Sclerosis with Interstitial Lung Disease Fund, managed by the HealthWell Foundation, aims to reduce financial barriers for underinsured patients suffering from systemic sclerosis. This rare autoimmune disease leads to excessive collagen production, causing serious health issues. The fund assists with prescription copays and insurance premiums to ensure patients receive necessary treatments. In 2024, HealthWell awarded over $1.2 billion in grants, supporting more than 1.1 million patients in accessing vital healthcare services.

The Porphyrias Fund, managed by the HealthWell Foundation, aims to alleviate financial burdens for underinsured patients suffering from porphyrias, a group of eight disorders characterized by the accumulation of porphyrins in the body. The fund assists with prescription drug copays and insurance premiums, offering up to $4,000 in financial aid. Established to ensure no patient lacks necessary treatment due to costs, the foundation has awarded over $1.2 billion since 2004, supporting more than 1.1 million patients.

The ACS - Fanconi Cancer Foundation Discovery Boost Grant invites innovative proposals for translational cancer research addressing the challenges faced by individuals with Fanconi anemia (FA). This grant supports high-risk, high-reward projects aimed at improving detection, prevention, or treatment of FA-related cancers. With funding of up to $135,000 per year for two years, it encourages research in early detection technologies, prevention mechanisms, and therapeutic strategies tailored to the unique sensitivities of the FA population.

The Metabolic Dysfunction-Associated Steatohepatitis Fund, established by the HealthWell Foundation, aims to alleviate financial burdens for underinsured patients facing chronic illnesses. It provides critical support for expenses related to prescription copays, insurance premiums, and transportation for treatment. With a maximum award of $8,000, the fund ensures that individuals can access necessary healthcare services without financial strain. This initiative emphasizes the commitment to improving health outcomes for those affected by metabolic dysfunction-associated steatohepatitis.

The Mantle Cell Lymphoma Fund, managed by the HealthWell Foundation, provides financial assistance to underinsured patients diagnosed with Mantle Cell Lymphoma. The fund covers prescription drug copays and Medicare Part B premiums, with a maximum award of $8,500. Eligible patients must have insurance that covers their medication and meet specific income guidelines. The foundation aims to reduce financial barriers to essential treatments, ensuring that patients receive necessary care without undue financial strain.

The HealthWell Foundation's Inborn Metabolic or Genetic Bile Acid Deficiency Vitamins and Supplements Fund provides essential financial assistance for individuals facing significant health challenges. By covering copays, deductibles, and related expenses, the fund aims to alleviate the financial burden on underinsured patients. With a commitment to enhancing healthcare access, the Foundation has awarded over $1.2 billion since its inception, ensuring that vital treatments remain accessible to those in need.

The Hyperoxaluria Fund, managed by the HealthWell Foundation, aims to alleviate financial burdens for underinsured patients suffering from hyperoxaluria, a condition characterized by excessive oxalate in urine. This fund assists with prescription drug copays and insurance premiums, providing vital support for treatments. In 2024 alone, HealthWell allocated over $1.2 billion in grants, ensuring access to essential medications for those in need. The organization is committed to improving healthcare access and reducing disparities for affected individuals.

The Emergency/Medical Workers Behavioral Health Fund aims to support emergency workers facing trauma and anxiety due to their roles. Established by the HealthWell Foundation, it provides financial assistance for treatment-related costs, including copayments for prescription drugs, counseling, and transportation. In 2024, the Foundation awarded over $1.2 billion to underinsured patients, ensuring no one is denied essential healthcare due to financial barriers. This initiative helps address the critical mental health needs of those who serve on the front lines.

The Dupuytren’s Disease Fund, managed by the HealthWell Foundation, aims to reduce financial barriers for underinsured patients suffering from Dupuytren's Disease. This fund provides assistance for prescription drug copays and insurance premiums related to treatment. With an average grant utilization of $1,650 over a 12-month period, the fund ensures that essential medications and therapies are affordable. HealthWell Foundation, a private non-profit, has helped over 1.1 million patients since 2004, demonstrating its commitment to healthcare access.

The Cushing's Disease or Cushing's Syndrome Fund, operated by the HealthWell Foundation, provides vital financial assistance to underinsured patients facing high medical costs associated with these conditions. The fund covers co-payments, insurance premiums, and necessary treatments, ensuring that patients receive the care they need without financial burden. With an average grant utilization of $3,000 over twelve months, this fund aims to alleviate the challenges of treatment accessibility, supporting both physical and mental health for those affected.

The Congenital Sucrase-Isomaltase Deficiency Fund, managed by the HealthWell Foundation, aims to alleviate financial burdens for underinsured patients suffering from this genetic disorder. By providing assistance with prescription drugs and treatment costs, the fund ensures that vital medications are accessible, allowing patients to manage their condition effectively. In 2024, the Foundation is expected to award over $1.2 billion in grants, showcasing its commitment to enhancing healthcare access for those in need.

The Chronic Lymphocytic Leukemia Fund, managed by the HealthWell Foundation, aims to alleviate financial burdens for underinsured patients battling chronic lymphocytic leukemia (CLL). This fund provides essential support for prescription copays and premiums, ensuring that patients can access necessary treatments without the stress of financial constraints. Since its inception, the foundation has awarded over $1.2 billion in grants, helping more than 1.1 million patients. The initiative emphasizes the importance of accessible healthcare and aims to improve the quality of life for those affected by this condition.

The CFSI Education Fund Scholarship, offered by the Community Foundation of Southern Indiana, awards multiple $2,000 non-renewable scholarships to students over 25 who have some college experience but no degree. This program aims to support those returning to complete their post-secondary education, including vocational training. By empowering individuals from Clark and Floyd counties, the scholarship fosters educational advancement and community growth, reflecting the foundation's commitment to enriching lives through learning.

The National Scleroderma Foundation's Pre-Doctoral Summer Fellowship Award Program aims to support Ph.D. students conducting vital research on scleroderma. This initiative encourages emerging researchers by fostering their early interest in discovering the causes and potential cures of this challenging disease. By funding innovative research, the Foundation seeks to advance medical knowledge and improve the lives of those affected by scleroderma, reinforcing its commitment to finding a cure.